Status:
COMPLETED
Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Psoriatic Arthritis (PsA)
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is a long-term, observational study of Abatacept in patients with Psoriatic Arthritis, a chronic inflammatory disorder.
Eligibility Criteria
Inclusion
- Participants 18 years or older
- Participants who signed an informed consent
- Participants diagnosed with PsA as per the criteria of the Classification of Psoriatic Arthritis (CASPAR) Study Group18
- Participants naïve of abatacept and who at their physician's discretion initiate abatacept
- Participants meeting criteria for abatacept treatment for PsA as specified in the German label
Exclusion
- Participants who are currently included in any interventional clinical trial in PsA/Rheumatoid Arthritis (RA)
Key Trial Info
Start Date :
March 2 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 31 2022
Estimated Enrollment :
190 Patients enrolled
Trial Details
Trial ID
NCT03419143
Start Date
March 2 2018
End Date
March 31 2022
Last Update
May 31 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution - 0001
Nuremberg, Germany, 90429